Clinical Trial

MVX-ONCO-2 in Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
MVX-ONCO-2 is a patient-specific, cell-based, active immunotherapy where the participant's immune response to their own tumor cells is stimulated and/or increased. MVX-ONCO-2 is composed of a cell suspension of irradiated autologous tumor cells and two capsules loaded with allogenic genetically modified cells releasing an immunomodulator, granulocyte-macrophage colony stimulating factor (GM-CSF). MVX-ONCO-2 is an evolution of MVX-ONCO-1, which was approved for clinical investigation under the same category in a phase I and a phase II clinical trials. The objectives of the trial are to investigate the safety, tolerability and signals of efficacy of MVX-ONCO-2 in participants with advanced solid tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-09-28; most recent amendment 2026-04-08.
Status change: Recruiting → Active, Not Recruiting 2026-04-08
Status change: Withdrawn → Recruiting 2024-10-10
Status change: Not Yet Recruiting → Withdrawn 2023-01-27
Trial Details
NCT Number NCT05071846
Lead Sponsor University Hospital, Geneva
Conditions Solid Tumor, Adult
Enrollment 6 participants
Start Date 2024-10-22
Primary Completion 2026-11 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-14